Document Detail


Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy?
MedLine Citation:
PMID:  20350703     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Myocardial biopsy can be used for the detection of viral genome in dilated cardiomyopathy (DCM). Pilot studies have previously reported beneficial effects on clinical outcome and safety of an antiviral therapy using interferon beta-1b in chronic viral DCM. METHODS AND RESULTS: Myocardial biopsies were taken from patients with DCM. Using polymerase chain reaction and Southern Blot analysis, viral genome could be detected in 49% of patients. In 42 patients with viral infection, off-label use with interferon beta-1b was initiated. A further 68 patients formed the control group. The outcome was evaluated after follow-up with echocardiography, exercise electrocardiogram, and New York Heart Association class. A total of 81 men and 29 women with a median left ventricular ejection fraction of 34% were included. The follow-up period was 36 months. In 33 (79%) patients with interferon beta-1b treatment, minor adverse reactions occurred, but no major adverse events were reported. No significant benefit for interferon beta-1b treatment on clinical outcome could be detected during follow-up. CONCLUSIONS: Off-label use with interferon beta-1b in patients with viral DCM is feasible and safe under routine clinical practice. Concerning the herein evaluated clinical outcome parameters, promising results from pilot studies could not be confirmed. High prevalence of parvovirus B19 (92%) might influence the results.
Authors:
Oliver Zimmermann; Christoph Rodewald; Michael Radermacher; Martin Vetter; Juliane M Wiehe; Magdalena Bienek-Ziolkowski; Vinzenz Hombach; Jan Torzewski
Related Documents :
14640393 - A once-daily haart regimen containing indinavir + ritonavir plus one or two nucleoside ...
10770543 - The effect of treatment intensification in hiv-infection: a study comparing treatment w...
8570313 - Mri marrow observations in thalassemia: the effects of the primary disease, transfusion...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-02-07
Journal Detail:
Title:  Journal of cardiac failure     Volume:  16     ISSN:  1532-8414     ISO Abbreviation:  J. Card. Fail.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-30     Completed Date:  2010-10-29     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9442138     Medline TA:  J Card Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  348-56     Citation Subset:  IM    
Copyright Information:
(c) 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Internal Medicine II - Cardiology, University of Ulm, Ulm, Germany. oliver.zimmermann@uniklinik-ulm.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Cardiomyopathy, Dilated / drug therapy*,  genetics,  virology*
Chronic Disease
Female
Follow-Up Studies
Genome, Viral* / genetics
Humans
Interferon-beta / physiology*,  therapeutic use*
Longitudinal Studies
Male
Middle Aged
Multicenter Studies as Topic / trends
Randomized Controlled Trials as Topic / trends
Retrospective Studies
Virus Diseases / drug therapy*,  genetics,  virology*
Young Adult
Chemical
Reg. No./Substance:
145155-23-3/interferon beta-1b; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  What are the Thromboembolic Risks of Heart Failure Combined With Chronic or Paroxysmal AF?
Next Document:  Effects of Adipose Tissue-Derived Stem Cell Therapy After Myocardial Infarction: Impact of the Route...